Regulatory Compliance and AGM Details

Granules India Limited submitted its Integrated Annual Report for FY 2025-26 and notice of the 35th Annual General Meeting scheduled for August 6, 2026 via video conferencing, in compliance with SEBI LODR Regulations. The AGM will consider adoption of financial statements, declaration of final dividend, and re-appointment of directors including Ms. Priyanka Chigurupati.

Financial Performance Overview

Consolidated Performance (₹ in Millions):

  • Revenue: ₹53,656.42 (20% YoY growth from ₹44,816.08)
  • EBITDA: ₹11,851.44 (25% YoY growth from ₹9,452.36)
  • PAT: ₹5,950.21 (19% YoY growth from ₹5,015.16)
  • Gross Margin: 65.0% (structural expansion of ~1,500 bps since FY2022)

Business Segment Performance:

  • Finished Dosages: 74% of revenue (₹39,893 million, 16% growth)
  • APIs: 13% of revenue (₹6,822 million, 10% growth)
  • PFIs: 10% of revenue (₹5,348 million, 25% growth)
  • Peptide/CDMO: 3% of revenue (₹1,593 million, new growth platform)

Strategic Developments and Capital Raising

The company completed acquisition of Senn Chemicals AG (Switzerland), entering the peptide CDMO space, which turned EBITDA-positive in Q4FY26. The board approved preferential issuance of 51.28 million equity shares at ₹585 per share raising ₹3,000 million and 25 million convertible warrants receiving ₹3,656.25 million as 25% consideration, totaling ₹6,656.25 million for business operations and subsidiary funding.

Operational Challenges

The company faced operational challenges from a USFDA warning letter received for Gagillapur facility in February 2025, requiring voluntary pause in manufacturing and distribution operations during September 2024. This resulted in increased consultancy expenses (₹802.15 million vs ₹524.33 million) and air freight costs during remediation efforts.

ESG and Sustainability Achievements

Environmental Performance:

  • SBTi-validated climate targets aligned with 1.5°C pathway and net zero commitment by 2050
  • EcoVadis Gold rating (top 5% globally) and CDP Climate Change 'A' rating
  • Total Scope 1+2 Emissions: 62,421 tCO2e with 45.7% absolute reduction from FY23 baseline
  • 98% renewable electricity consumption and 80,000 MWh I-RECs procurement
  • Gagillapur facility achieved Zero Waste to Landfill Platinum Plus certification

Resource Management:

  • Total water consumption: 239,951 KL with 6.91 KL/million rupees turnover intensity
  • Total waste generated: 8,537.5 MT with 7,533.63 MT recovered through recycling/re-use
  • Energy savings: 2,309,552 kWh with annual cost savings of ₹176.4 lakhs

Social and Governance:

  • Total employees: 4,306 with 10.8% female representation
  • CSR expenditure: ₹112.73 million focused on education, healthcare, and skill development
  • Board composition: 11 directors (4 Executive, 1 Non-Executive, 6 Independent) with 97% meeting attendance
  • Comprehensive ESG governance structure with Board-level Sustainability and CSR Committee

Manufacturing and Regulatory Compliance

The company operates 10 manufacturing facilities globally with 39+ billion annual finished dosage capacity. Six of eight facilities hold clean EIR position, while R&D investment reached ₹2,853 million (5.3% of revenue) with 148 dossiers filed globally including 59 complex generics. All facilities certified to ISO 14001, ISO 45001, and SA8000 Social Accountability standards.

Dividend and Shareholder Returns

The board recommended a final dividend of ₹1.75 per equity share (face value ₹1 per share), with total dividend payout of ₹433.64 million for FY26. The Register of Members will be closed from July 31 to August 6, 2026 for AGM purposes, with dividend payment scheduled on or before September 4, 2026.

Independent Assurance and Compliance

Environmental data assured by Bureau Veritas with reasonable assurance for BRSR Core parameters. The company confirmed compliance with Companies Act, Indian Accounting Standards, SEBI LODR Regulations, GRI 2021 standards, TCFD recommendations, UNGC principles, and SASB guidelines across all operations.